Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
featured
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).

polycythemia
ruxolitinib
stem cell transplantation
essential thrombocythemia
bone marrow procedure
  • 1 views
  • 01 Sep, 2021
  • 37 locations
Azacitidine and Homoharringtonine in JMML

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine

refractory acute myeloid leukemia (aml)
myeloid leukemia
azacitidine
  • 0 views
  • 25 Jan, 2021
  • 1 location
Study of ASTX727 vs IV Decitabine in MDS CMML and AML

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily5 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily5 in Cycle 2, or the converse order. After completion of …

secondary acute myeloid leukemia
blast cells
conjugated bilirubin
anemia
secondary aml
  • 269 views
  • 27 Jan, 2021
  • 93 locations
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line setting and are not

cmml-2
stem cell transplantation
myelomonocytic leukemia
cell transplantation
azacitidine
  • 5 views
  • 09 Sep, 2021
  • 131 locations
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS) Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (AML)

defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants with low-blast AML).

myeloid leukemia
blast cells
myelomonocytic leukemia
myelodysplastic syndromes
azacitidine
  • 341 views
  • 21 Aug, 2021
  • 324 locations
A Study of H3B-8800 in Participants With Myelodysplastic Syndromes Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

-8800 in subset of participants with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). The study consists of two parts, a dose escalation part

myeloid leukemia
blood transfusion
hydroxyurea
myelomonocytic leukemia
myelodysplastic syndromes
  • 0 views
  • 23 Mar, 2021
  • 27 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

blast cells
hematologic malignancy
IDH2
  • 0 views
  • 16 Sep, 2021
  • 47 locations
Study to Assess Safety Tolerability Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.

progressive disease
chronic lymphocytic leukemia
lymphocytic leukemia
secondary acute myeloid leukemia
richter syndrome
  • 98 views
  • 03 Sep, 2021
  • 23 locations
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.

myeloproliferative disorder
chronic myelomonocytic leukemia
  • 4 views
  • 22 Aug, 2021
  • 4 locations
Tagraxofusp (SL-401) in Patients With CMML or MF

This multi-center, multi-arm trial is evaluating the safety and efficacy of tagraxofusp, a CD123-targeted therapy, in patients with either chronic myelomonocytic leukemia (CMML) or myelofibrosis

cmml-2
monocytosis
neutrophil count
dysplasia
ejection fraction
  • 145 views
  • 16 Aug, 2021
  • 13 locations